Clinically, the heterogeneous breast cancer is categorized into four distinct molecular subgroups (2, 4): Luminal A and luminal B breast cancers are broadly defined as those with estrogen receptor (ERs) positive expression, which response to the antiestrogen therapy. This evidence concerns the gene ESR1 and breast carcinoma.